ALK-5 Inhibition: A Molecular Interpretation of the Main Physicochemical Properties Related to Bioactive Ligands

被引:6
作者
Araujo, Sheila C. [1 ]
Maltarollo, Vinicius G. [1 ]
Silva, Danielle C. [1 ]
Gertrudes, Jadson C. [2 ]
Honorio, Kathia M. [1 ,2 ]
机构
[1] Univ Fed ABC, Ctr Ciencias Nat & Humanas, BR-09210170 Santo Andre, SP, Brazil
[2] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, BR-03828000 Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
ALK-5; cancer; molecular modeling; feature selection; QSAR; TGF-BETA; APPLICABILITY DOMAIN; CANCER STATISTICS; RECEPTOR; QSAR; VALIDATION; DERIVATIVES; DESIGN; POTENT; CLASSIFICATION;
D O I
10.5935/0103-5053.20150172
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Activin-like kinase 5 (ALK-5) receptor represents an attractive object to treat cancer. Analyses on the quantitative structure-activity relationship were performed to explore the relationship between the molecular structure of 1,5-naphthyridine, pyrazole and quinazoline derivatives and the inhibition of the activin-like kinase 5. From a data set containing 59 compounds, various electronic descriptors were calculated using density functional theory (DFT) method; stereochemical descriptors (as molecular volume and area), polar surface area (PSA), log P and dragon descriptors were also calculated. The ordered predictor selection (OPS) algorithm, weighted principal component analysis (PCA) and Fisher's weights (FW), combined with sequential forward selection, were employed to select the most relevant descriptors to be employed in all partial least square regressions. Using this procedure, we selected the most informative descriptors and significant correlation coefficients were achieved (r(2) = 0.74, q(2) = 0.83). Additional validation tests were carried out, indicating that the obtained model is robust and reliable and, consequently, it can be used to predict the biological activity of new compounds.
引用
收藏
页码:1936 / 1946
页数:11
相关论文
共 65 条
[1]   Targeting the TGFβ signalling pathway in disease [J].
Akhurst, Rosemary J. ;
Hata, Akiko .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) :790-811
[2]  
[Anonymous], QSAR DRUG DESIGN THE
[3]  
[Anonymous], 2002, Series: Springer Series in Statistics
[4]  
[Anonymous], QUIM NOVA
[5]  
[Anonymous], HYPERCHEM VERS 8 0
[6]  
[Anonymous], 1986, ANAL CHIM ACTA, DOI DOI 10.1016/0003-2670(86)80028-9
[7]  
[Anonymous], SPART VERS 08
[8]  
[Anonymous], PIR VERS 3 11
[9]  
[Anonymous], 2009, MATLAB
[10]  
[Anonymous], SYB VERS 8 1